We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » OIG SAYS MEDICARE OVERPAYS FOR LUPRON, TWO RESPIRATORY DRUGS
OIG SAYS MEDICARE OVERPAYS FOR LUPRON, TWO RESPIRATORY DRUGS
February 3, 2004
Medicare and its beneficiaries could save nearly $700 million a year if the program’s reimbursement rates for three drugs — Lupron, albuterol and ipratropium bromide — were more in line with what purchasers pay to obtain them, according to the HHS Office of Inspector General (OIG).